Does using daratumumab make response-monitoring difficult? (https://www.myeloma.org/videos/does-using-daratumumab-make-response-monitoring-difficult)

>


In this week’s video, Dr. Brian G.M. Durie explains how daratumumab may interfere with response-monitoring and with blood transfusions for myeloma patients.

BOTTOM LINE:
If you are taking dara, discuss response-monitoring with your doctor. 

If you have a question that you’d like to suggest for a future episode of Ask Dr. Durie, please submit it to [email protected] (mailto:[email protected])

To reach the IMF InfoLine Coordinators, please call 800.452.2873 or email them at [email protected] (mailto:[email protected])


Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

Video
Old Id
696

Source URL: https://www.myeloma.org/videos/does-using-daratumumab-make-response-monitoring-difficult